Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 54 of 494 for:    penis

International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) (InPACT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02305654
Recruitment Status : Recruiting
First Posted : December 2, 2014
Last Update Posted : October 31, 2019
Sponsor:
Collaborators:
National Cancer Institute (NCI)
ECOG-ACRIN Cancer Research Group
Canadian Cancer Trials Group
Information provided by (Responsible Party):
Institute of Cancer Research, United Kingdom

Brief Summary:

This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment. The study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. It will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provide data to inform future clinical decisions.

InPACT-neoadjuvant patients are stratified by disease burden as assessed by radiological criteria. Treatment options are then defined according to the disease burden strata. Treatment is allocated by randomisation. Patients may be allocated to one of three initial treatments:

A. standard surgery (ILND); B. neoadjuvant chemotherapy followed by standard surgery (ILND); or C. neoadjuvant chemoradiotherapy followed by standard surgery (ILND).

After ILND, patients are defined as being at low or high risk of recurrence based on histological interpretation of the ILND specimen. Patients at high risk of relapse are eligible for InPACT-pelvis, where they are randomised to either:

P. prophylactic PLND Q. no prophylactic PLND


Condition or disease Intervention/treatment Phase
Squamous Cell Carcinoma of the Penis, Usual Type Procedure: ILND - Inguinal Lymph Node Dissection Drug: Paclitaxel Drug: Ifosfamide Drug: Cisplatin Radiation: Intensity modulated radiation treatment (IMRT) Procedure: Prophylactic PLND - pelvic lymph node dissection Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Actual Study Start Date : May 12, 2017
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : July 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Arm A - Standard Surgery (ILND)

Part of randomisation 1.

The total treatment duration (Inguinal Lymph Node Dissection (ILND)) is estimated to be over 1 day for those patients allocated to Arm A - standard surgery.

Procedure: ILND - Inguinal Lymph Node Dissection
Surgery to remove the lymph nodes in the groin near to where the cancer first appeared.

Experimental: Arm B - neoadjuvant chemotherapy

Part of randomisation 1.

Patients will receive up to 4 cycles of Paclitaxel, Ifosfamide, and Cisplatin (TIP).

Administration on an outpatient basis:

Paclitaxel 175 mg/m2, day 1, Ifosfamide 900 mg/m2, days 2-5, Cisplatin 15 mg/m2, days 1-5

Administration on an inpatient basis:

Paclitaxel 175 mg/m2, day 1, Ifosfamide 1200 mg/m2, days 1-3, Cisplatin 25 mg/m2, days 1-3

Drug: Paclitaxel
Dose 175mg/m2 as part of TIP regimen.
Other Name: Taxol

Drug: Ifosfamide
Dose 900mg/m2 as part of TIP regimen.
Other Name: Mitoxana

Drug: Cisplatin
Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)

Experimental: Arm C - neoadjuvant chemoradiotherapy

Part of randomisation 1.

Radiotherapy dose is 45Gy in 25 fractions over 5 weeks using 6-10 MV photons to all regions.

Concurrent cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min.

Drug: Cisplatin
Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)

Radiation: Intensity modulated radiation treatment (IMRT)
Treatment with very high energy X-rays (radiotherapy).

Experimental: Arm P - prophylactic PLND

Part of randomisation 2.

Prophylactic pelvic lymph node dissection (PLND) - The total treatment duration is estimated to be over 1 day.

Patients who have NOT received neoadjuvant chemoradiotherapy will receive adjuvant chemoradiotherapy:

Cisplatin 40mg/m2 will be given weekly, subject to GFR>45mls/min.

Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour

Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:

  1. Any macroscopic tumour or pathological lymph nodes
  2. Electively to external iliac nodes in patient with high disease burden

Patients who have had neoadjuvant chemoradiotherapy will have prophylactic PLND alone.

Procedure: Prophylactic PLND - pelvic lymph node dissection
Surgery to remove the lymph nodes deeper in the pelvis, further away from where the cancer first appeared, that are at high risk of harbouring cancer.

No Intervention: Arm Q - Surveillance no prophylactic PLND

no prophylactic PLND Part of randomisation 2.

For patients who have NOT received neoadjuvant chemoradiotherapy:

Groin: One or both groins may be boosted up to 54Gy in 25 fractions. An IMRT boost of up to 57 Gy can be given to recurrent or residual macroscopic tumour

Pelvis: the dose is limited to 45Gy unless IMRT is available. An IMRT boost of up to 54Gy in 25 fractions is applied to:

Any macroscopic tumour or pathological lymph nodes Electively to external iliac nodes in patient with high disease burden




Primary Outcome Measures :
  1. Overall survival [ Time Frame: up to 5 years ]
    The primary outcome measure that will be measured for all trial patients is survival time. This is defined in whole days as the time from the date of randomisation to the date of death from any cause; for those who have not been reported as dead at the time of analysis, the survival time will be censored at the date of last follow-up.


Secondary Outcome Measures :
  1. Disease specific survival time [ Time Frame: up to 5 years ]
    Disease-specific survival time which is defined in whole days as the time from the date of randomisation to the date of death specifically from disease; for those who have not been reported as dead at the time of analysis, the survival time will be censored at the date of last follow-up and for those whose death is reported as non-disease specific then the survival time will be censored at date of death.

  2. Number of patients experience a grade 3 or 4 toxicity [ Time Frame: up to 5 years ]
  3. Disease-free survival time [ Time Frame: up to 5 years ]

    Disease-free survival time (DFST) which is defined in whole days as the time from date of randomisation to the date of either locoregional recurrence, distant metastasis or death from disease, whichever occurs first; for those who have not been reported as experiencing any of these events, the DFST will be censored at the date last known to be alive and free of disease or date of non-disease-specific death. A supplementary exploratory outcome measure will also be calculated taking date of penectomy as the origin rather than date of randomisation.

    Subsidiary outcome measures will be

    • locoregional recurrence free survival time (LRFST).
    • distant metastases free survival time (DMFST).
    • A supplementary exploratory outcome measure will also be calculated taking date of penectomy as the origin for all these outcome measures rather than date of randomisation.

  4. Occurrence of surgical complication [ Time Frame: up to 5 years ]
  5. Is it possible to achieve pathological nodal assessment after chemotherapy [ Time Frame: 12 weeks ]
    Feasibility of pathological nodal assessment after chemotherapy which is recorded as whether or not it was possible to achieve a pathological nodal assessment after chemotherapy.

  6. Quality of life [ Time Frame: Baseline, 3, 6, 9, 12, 18, 24 and 36 months ]
    Measured using the EORTC-QLQC30 and Lymphodema-QL

  7. Occurrence of Pathological complete remission [ Time Frame: Time to complete remission after randomisation ]

    Measured for all patients in InPACT-neoadjuvant:

    Absolute absence of disease on histological examination


  8. Operability [ Time Frame: 2-6 weeks ]
    Measured for all trial patients in InPACT-neoadjuvant. Operability which will be recorded as whether or not the planned inguinal node dissection was undertaken and the reasons if it did not occur.

  9. Occurrence of Lower limb/scrotal oedema [ Time Frame: up to 5 years ]
    Occurrence of Lower limb/scrotal oedema which is recorded as whether or not the patient experiences a lower limb or scrotal oedema

  10. On-schedule delivery of neoadjuvant therapy [ Time Frame: After randomisation up to 12 weeks ]
    Feasibility of on-schedule delivery of neoadjuvant therapy


Other Outcome Measures:
  1. Acceptability of randomisation [ Time Frame: up to 5 years ]
    In addition to the outcome measures, the acceptability of both randomisations will be monitored based on the proportion of eligible patients approached for randomisation, the proportion of approached patients consenting to randomisation and the proportion of randomised patients receiving their allocated treatment. This will provide ongoing information regarding the feasibility of the trial successfully completing to target.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Written informed consent
  2. Measurable disease as determined by RECIST (version 1.1) criteria;
  3. Histologically-proven squamous cell carcinoma of the penis,
  4. Stage:

    • any T, N1 (i.e. a palpable mobile unilateral inguinal lymph node), M0 or;
    • any T, N2 (i.e. palpable mobile multiple or bilateral inguinal lymph nodes), M0 or;
    • any T, N3 (i.e. fixed inguinal nodal mass or any pelvic lymphadenopathy), M0
  5. Performance Status ECOG 0, 1 or 2.

Exclusion Criteria:

  1. Pure verrucous carcinoma of the penis,
  2. Nonsquamous malignancy of the penis,
  3. Squamous carcinoma of the urethra,
  4. Stage M1,
  5. Previous chemotherapy or chemoradiotherapy,
  6. Concurrent malignancy (other than SCC or Basal Cell Carcinoma of non-penile skin) that has required surgical or non-surgical treatment in the last 3 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02305654


Contacts
Layout table for location contacts
Contact: UK - InPACT Senior Trial Manager 02087224261 InPACT-icrctsu@icr.ac.uk
Contact: US/Canada - InPACT DA for EA8134 (857)504-2900

Locations
Layout table for location information
United States, California
Los Angeles County-USC Medical Center Recruiting
Los Angeles, California, United States, 90033
Contact: Anne Schuckman    323-865-3700    anne.schuckman@med.usc.edu   
USC / Norris Comprehensive Cancer Center Recruiting
Los Angeles, California, United States, 90033
Contact: Sia Daneshmand    323-865-3700    daneshma@usc.edu   
United States, Florida
Moffitt Cancer Center Recruiting
Tampa, Florida, United States, 33612
Contact: Phil Spiess    813-745-8343    Philippe.spiess@moffitt.org   
United States, Georgia
Grady Health System Active, not recruiting
Atlanta, Georgia, United States, 30303
Emory University Hospital/Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Viraj Master    404-778-4898    vmaster@emory.edu   
United States, Illinois
University of Chicago Comprehensive Cancer Center Active, not recruiting
Chicago, Illinois, United States, 60637
United States, Minnesota
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: Lance Pagliaro       pagliaro.lance@mayo.edu   
Contact: Stephen Boorjian /Jeffrey Karnes (karnes.r@mayo.edu)    (507)284-4015 / (507)266-9968    boorjian.stephen@mayo.edu   
United States, Ohio
Ohio State University Comprehensive Cancer Center Active, not recruiting
Columbus, Ohio, United States, 43210
United States, Oklahoma
University of Oklahoma Health Sciences Center Active, not recruiting
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
Fox Chase Cancer Center Active, not recruiting
Philadelphia, Pennsylvania, United States, 19111
United States, Texas
University of Texas M.D. Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Curtis Pettaway    713-792-3250    cpettawa@mdanderson.org   
United Kingdom
Velindre NHS Trust Recruiting
Cardiff, United Kingdom, CF14 2TL
Contact: Dr James Barber         
University Hospitals of Leicester NHS Trust Recruiting
Leicester, United Kingdom, LE1 5WW
Contact: Dr Christopher Kent         
The Royal Marsden NHS Foundation Trust Active, not recruiting
London, United Kingdom, SM2 5PT
St George's Hospital NHS Foundation Trust Recruiting
London, United Kingdom, SW17 0QT
Contact: Mr Nick Watkin         
Norfolk and Norwich University Hospitals NHS Foundation Trust Recruiting
Norwich, United Kingdom, NR4 7UY
Contact: Mr Vivekanandan Kumar         
Swansea Bay University Health Board Active, not recruiting
Swansea, United Kingdom, SA6 6NL
Sponsors and Collaborators
Institute of Cancer Research, United Kingdom
National Cancer Institute (NCI)
ECOG-ACRIN Cancer Research Group
Canadian Cancer Trials Group
Investigators
Layout table for investigator information
Study Chair: Steve Nicholson Southend University Hospital Foundation NHS Trust
Study Chair: Curtis Pettaway University of Texas M.D. Anderson Cancer Center ; 713-792-3250 ; cpettawa@mdanderson.org

Additional Information:
Layout table for additonal information
Responsible Party: Institute of Cancer Research, United Kingdom
ClinicalTrials.gov Identifier: NCT02305654     History of Changes
Other Study ID Numbers: ICR CTSU/2014/10048
CRUK/13/005 ( Other Grant/Funding Number: Cancer Research UK )
13580965 ( Registry Identifier: ISRCTN )
EA8134 ( Other Grant/Funding Number: NCI )
IRCI004 ( Other Identifier: IRCI )
2015-001199-23 ( EudraCT Number )
First Posted: December 2, 2014    Key Record Dates
Last Update Posted: October 31, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Institute of Cancer Research, United Kingdom:
Penis cancer
Chemotherapy
Chemoradiotherapy
Surgery
Phase III
Additional relevant MeSH terms:
Layout table for MeSH terms
Paclitaxel
Albumin-Bound Paclitaxel
Cisplatin
Ifosfamide
Isophosphamide mustard
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating
Alkylating Agents